Raymond Debbane Reports 6.1% Of Rezolute Through Two Fund Ownership Chains

The ownership percentage uses Rezolute's share count after Monday's public offering, though the reported holdings date was Friday.

Share
Raymond Debbane Reports 6.1% Of Rezolute Through Two Fund Ownership Chains

Raymond Debbane reported a 6.1% beneficial stake in Rezolute, which develops treatments for dangerously low blood sugar, in an SEC passive ownership disclosure filed Thursday. The 7,204,256 shares attributed to him were held directly by funds in ownership chains he controls.

Two Funds, One Attributed Stake

Invus Public Equities, a Bermuda limited partnership, directly owned 6,319,631 shares as of Friday. Avicenna Life Sci Master Fund, a Cayman Islands limited partnership, held another 884,625 shares directly.

Debbane is the managing member of Siren and Ulys, the entities atop the respective ownership chains. His control of those entities is the basis for attributing both funds' shares to him as beneficial ownership.

Siren controls Invus Global Management, which controls Invus Public Equities Advisors, the general partner controlling Invus Public Equities. Ulys controls Avicenna Life Sci Master GP, the general partner controlling the Avicenna fund.

Debbane reported sole authority to vote all 7,204,256 shares attributed to him. All reporting investors listed zero shared voting authority and certified that their holdings were acquired and maintained without an aim to change or influence Rezolute's control.

A Post-Offering Ownership Base

Rezolute closed its public offering Monday. The ownership percentages use the 118,763,309 shares outstanding after that closing, drawing on Rezolute's offering prospectus filed Monday, even though the holdings were dated Friday.

On that basis, the Invus stake represented 5.3% of the common-stock class and the Avicenna stake represented 0.7%. Debbane's reported percentage covers the shares attributed through both chains.

Ersodetug Leads The Research Effort

Rezolute has no approved products. Its lead drug candidate, ersodetug, is an antibody delivered intravenously and being studied for low blood sugar associated with excess insulin activity.

The research covers congenital hyperinsulinism, which affects children, and hyperinsulinism caused by tumors. Rezolute also supplies ersodetug through an expanded access program for patients unable to enter a clinical trial.

Research and development spending totaled about $53.8 million in the fiscal year ended June 30, 2026. At that date, 40 of its 58 full-time employees worked in research and development; all employees were in the United States.

Sources

More on Rezolute

All Rezolute (RZLT) coverage →